Coraline Dubot

9.6k total citations · 2 hit papers
64 papers, 1.5k citations indexed

About

Coraline Dubot is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Coraline Dubot has authored 64 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Coraline Dubot's work include Endometrial and Cervical Cancer Treatments (19 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Cancer Genomics and Diagnostics (14 papers). Coraline Dubot is often cited by papers focused on Endometrial and Cervical Cancer Treatments (19 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Cancer Genomics and Diagnostics (14 papers). Coraline Dubot collaborates with scholars based in France, Italy and Japan. Coraline Dubot's co-authors include Nicoletta Colombo, Domenica Lorusso, Ronnie Shapira‐Frommer, Vincent Castonguay, Pamela Salman, Vanessa Samouëlian, Kosei Hasegawa, Krishnansu S. Tewari, Mivael Olivera and Bradley J. Monk and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Coraline Dubot

59 papers receiving 1.4k citations

Hit Papers

Pembrolizumab for Persistent, Recurrent, or Metastatic Ce... 2021 2026 2022 2024 2021 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    2021 581 citations Nicoletta Colombo, Coraline Dubot et al. profile →
  2. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
    2023 100 citations Bradley J. Monk, Nicoletta Colombo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Coraline Dubot France 15 883 410 371 305 277 64 1.5k
Vincent Castonguay Canada 11 563 0.6× 415 1.0× 229 0.6× 106 0.3× 239 0.9× 43 1.0k
Pamela Salman United States 11 646 0.7× 382 0.9× 190 0.5× 109 0.4× 253 0.9× 22 1.1k
Matthias Choschzick Germany 24 480 0.5× 311 0.8× 242 0.7× 250 0.8× 441 1.6× 51 1.4k
Yuko Sasajima Japan 19 375 0.4× 328 0.8× 225 0.6× 248 0.8× 235 0.8× 94 1.2k
Kevin Norwood United States 22 1.3k 1.5× 222 0.5× 504 1.4× 234 0.8× 779 2.8× 38 1.8k
Wataru Yamagami Japan 24 641 0.7× 763 1.9× 149 0.4× 349 1.1× 212 0.8× 124 2.0k
Holm Eggemann Germany 22 694 0.8× 245 0.6× 238 0.6× 651 2.1× 146 0.5× 76 1.6k
Dominique Berton-Rigaud France 18 1.0k 1.1× 405 1.0× 238 0.6× 277 0.9× 246 0.9× 73 1.8k
Jordi Xercavins Spain 26 490 0.6× 829 2.0× 151 0.4× 487 1.6× 364 1.3× 86 1.9k
Eduard Vrdoljak Croatia 15 435 0.5× 136 0.3× 617 1.7× 308 1.0× 167 0.6× 78 1.2k

Countries citing papers authored by Coraline Dubot

Since Specialization
Citations

This map shows the geographic impact of Coraline Dubot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Coraline Dubot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Coraline Dubot more than expected).

Fields of papers citing papers by Coraline Dubot

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Coraline Dubot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Coraline Dubot. The network helps show where Coraline Dubot may publish in the future.

Co-authorship network of co-authors of Coraline Dubot

This figure shows the co-authorship network connecting the top 25 collaborators of Coraline Dubot. A scholar is included among the top collaborators of Coraline Dubot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Coraline Dubot. Coraline Dubot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Colombo, Nicoletta, Coraline Dubot, Kazuki Hasegawa, et al.. (2024). Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study. Annals of Oncology. 36(1). 65–75. 9 indexed citations
2.
Monk, Bradley J., Nicoletta Colombo, Krishnansu S. Tewari, et al.. (2023). First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. Journal of Clinical Oncology. 41(36). 5505–5511. 100 indexed citations breakdown →
3.
Léary, Alexandra, Christophe Schneider, Elisa Yaniz‐Galende, et al.. (2023). CD47 expression in ovarian cancer: Dynamic correlation with lymphocyte and macrophage features as well as thrombospondin-1 (TSP-1) under neoadjuvant chemotherapy.. Journal of Clinical Oncology. 41(16_suppl). 5569–5569.
4.
5.
Pautier, Patricia, Catherine Genestie, Laurence Gladieff, et al.. (2023). Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer du col de l'utérus avancé. Bulletin du Cancer. 110(6). 6S44–6S50.
6.
7.
Gutierrez, Maya, Émilie Le Rhun, Olivier Trédan, et al.. (2022). Phase II study of intrathecal administration of trastuzumab in patients with HER2-positive breast cancer with leptomeningeal metastasis. Neuro-Oncology. 25(2). 365–374. 30 indexed citations
8.
Coquan, Elodie, Justine Lequesne, Émeline Colomba, et al.. (2022). 2022-RA-579-ESGO A phase II study assessing safety and efficacy of cabozantinib for advanced or metastatic cervical carcinoma after platinum treatment failure (CABOCOL study). International Journal of Gynecological Cancer. 32. A14–A14.
9.
Colombo, Nicoletta, Coraline Dubot, Domenica Lorusso, et al.. (2022). Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. Obstetrical & Gynecological Survey. 77(1). 30–31. 10 indexed citations
10.
Blanc‐Durand, Félix, Catherine Genestie, Étienne Rouleau, et al.. (2021). Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.. Journal of Clinical Oncology. 39(15_suppl). 5513–5513. 10 indexed citations
11.
Freyer, Gilles, Anne Floquet, Olivier Trédan, et al.. (2021). 733P Bevacizumab (Bev), olaparib (Ola) and durvalumab (Durva) in patients with recurrent advanced ovarian cancer (AOC): The GINECO BOLD study. Annals of Oncology. 32. S734–S735. 6 indexed citations
12.
13.
Jacot, William, Paul Cottu, Frédérique Berger, et al.. (2019). Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial. Breast Cancer Research. 21(1). 121–121. 56 indexed citations
14.
Pierga, J-Y, Étienne Brain, Roman Rouzier, et al.. (2019). Long-term survival in HER2-positive metastatic breast cancer treated with first-line trastuzumab: results from the french real-life curie database. Breast Cancer Research and Treatment. 178(3). 505–512. 7 indexed citations
15.
Bonneau, Claire, Gilles Paintaud, Olivier Trédan, et al.. (2018). Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. European Journal of Cancer. 95. 75–84. 66 indexed citations
16.
Fourme, Emmanuelle, Laurence Bozec, Florence Lerebours, et al.. (2018). Febrile neutropenia in adjuvant and neoadjuvant chemotherapy for breast cancer: a retrospective study in routine clinical practice from a single institution. Supportive Care in Cancer. 26(12). 4097–4103. 7 indexed citations
17.
Zida, M, et al.. (2018). So-called “historical” necrotic breast cancers: a terrifying actuality in Africa. The case of Burkina Faso. Médecine et Santé Tropicales. 28(4). 434–438.
18.
Cottu, Paul, Coraline Dubot, Laurence Venat‐Bouvet, et al.. (2017). Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial. Annals of Oncology. 28. v32–v32. 9 indexed citations
19.
Selle, Frédèric, et al.. (2012). Chimiothérapie des récidives des cancers de l’ovaire. 14(1). 51–62. 1 indexed citations
20.
Dubot, Coraline, et al.. (2012). Suivi en ville après un cancer du sein : satisfaction des patientes dans le Réseau Gynécomed île-de-France. Bulletin du Cancer. 99(10). 915–925. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vincent Castonguay Breakdown of academic impact, for papers by Pamela Salman Breakdown of academic impact, for papers by Matthias Choschzick Breakdown of academic impact, for papers by Yuko Sasajima Breakdown of academic impact, for papers by Kevin Norwood Breakdown of academic impact, for papers by Wataru Yamagami Breakdown of academic impact, for papers by Holm Eggemann Breakdown of academic impact, for papers by Dominique Berton-Rigaud Breakdown of academic impact, for papers by Jordi Xercavins Breakdown of academic impact, for papers by Eduard Vrdoljak
Rankless by CCL
2026